The Aralez Pharmaceuticals Inc. (ARLZ) Stock Rating Reaffirmed by Guggenheim

The Aralez Pharmaceuticals Inc. (ARLZ) Stock Rating Reaffirmed by Guggenheim

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)‘s stock had its “buy” rating reissued by equities researchers at Guggenheim in a report issued on Monday. They currently have a $12.00 price target on the stock. Guggenheim’s price target suggests a potential upside of 134.38% from the company’s current price.

Separately, Chardan Capital reiterated a “buy” rating and set a $10.00 price target on shares of Aralez Pharmaceuticals in a research report on Sunday, August 14th.

Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 5.12 on Monday. Aralez Pharmaceuticals has a 52-week low of $3.10 and a 52-week high of $8.59. The firm’s market cap is $334.03 million. The firm’s 50-day moving average price is $5.29 and its 200 day moving average price is $4.20.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its earnings results on Tuesday, August 9th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.08. Aralez Pharmaceuticals had a negative return on equity of 73.21% and a negative net margin of 224.35%. The firm had revenue of $12.60 million for the quarter, compared to the consensus estimate of $9.70 million. The firm’s revenue was up 142.3% on a year-over-year basis. On average, equities research analysts forecast that Aralez Pharmaceuticals will post ($1.06) EPS for the current year.

In other news, Director Robert Paul Harris sold 150,000 shares of the stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $5.82, for a total transaction of $873,000.00. Following the sale, the director now directly owns 669,094 shares in the company, valued at approximately $3,894,127.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.77% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. Drill Craig A boosted its stake in Aralez Pharmaceuticals by 72.3% in the second quarter. Drill Craig A now owns 584,600 shares of the company’s stock valued at $1,929,000 after buying an additional 245,300 shares in the last quarter. California Public Employees Retirement System boosted its stake in Aralez Pharmaceuticals by 10.0% in the second quarter. California Public Employees Retirement System now owns 105,867 shares of the company’s stock valued at $349,000 after buying an additional 9,667 shares in the last quarter. LMR Partners LLP acquired a new stake in Aralez Pharmaceuticals during the second quarter valued at approximately $145,000. FNY Managed Accounts LLC boosted its stake in Aralez Pharmaceuticals by 73.3% in the second quarter. FNY Managed Accounts LLC now owns 52,000 shares of the company’s stock valued at $172,000 after buying an additional 22,000 shares in the last quarter. Finally, Alps Advisors Inc. boosted its stake in Aralez Pharmaceuticals by 24.9% in the second quarter. Alps Advisors Inc. now owns 89,850 shares of the company’s stock valued at $297,000 after buying an additional 17,920 shares in the last quarter. Hedge funds and other institutional investors own 49.63% of the company’s stock.

Aralez Pharmaceuticals Company Profile

Related posts

Leave a Comment